150 related articles for article (PubMed ID: 24910381)
1. Alemtuzumab for severe steroid-refractory gastrointestinal acute graft-versus-host disease.
Meunier M; Bulabois CE; Thiebaut-Bertrand A; Itzykson R; Carre M; Carras S; Garban F; Cahn JY
Biol Blood Marrow Transplant; 2014 Sep; 20(9):1451-4. PubMed ID: 24910381
[TBL] [Abstract][Full Text] [Related]
2. Alemtuzumab as treatment of steroid-refractory acute graft-versus-host disease: results of a phase II study.
Martínez C; Solano C; Ferrá C; Sampol A; Valcárcel D; Pérez-Simón JA;
Biol Blood Marrow Transplant; 2009 May; 15(5):639-42. PubMed ID: 19361757
[TBL] [Abstract][Full Text] [Related]
3. Alemtuzumab for the treatment of steroid-refractory acute graft-versus-host disease.
Gómez-Almaguer D; Ruiz-Argüelles GJ; del Carmen Tarín-Arzaga L; González-Llano O; Gutiérrez-Aguirre H; Cantú-Rodríguez O; Jaime-Pérez J; Carrasco-Yalán A; Giralt S
Biol Blood Marrow Transplant; 2008 Jan; 14(1):10-5. PubMed ID: 18158956
[TBL] [Abstract][Full Text] [Related]
4. A Prospective Study of Alemtuzumab as a Second-Line Agent for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplantation.
Khandelwal P; Emoto C; Fukuda T; Vinks AA; Neumeier L; Dandoy CE; El-Bietar J; Chandra S; Davies SM; Bleesing JJ; Jordan MB; Mehta PA; Jodele S; Grimley MS; Kumar A; Myers KC; Marsh RA
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2220-2225. PubMed ID: 27664325
[TBL] [Abstract][Full Text] [Related]
5. Limited benefit of pentostatin salvage therapy for steroid-refractory grade III-IV acute graft-versus-host disease.
Alam N; Atenafu EG; Tse G; Viswabandya A; Gupta V; Kim D; Lipton JH; Messner HA; Kuruvilla J
Clin Transplant; 2013; 27(6):930-7. PubMed ID: 24304375
[TBL] [Abstract][Full Text] [Related]
6. Updated experience with inolimomab as treatment for corticosteroid-refractory acute graft-versus-host disease.
García-Cadenas I; Valcárcel D; Martino R; Piñana JL; Novelli S; Esquirol A; Garrido A; Moreno ME; Granell M; Moreno C; Saavedra S; Briones J; Brunet S; Sierra J
Biol Blood Marrow Transplant; 2013 Mar; 19(3):435-9. PubMed ID: 23178634
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic human mesenchymal stem cell therapy (remestemcel-L, Prochymal) as a rescue agent for severe refractory acute graft-versus-host disease in pediatric patients.
Kurtzberg J; Prockop S; Teira P; Bittencourt H; Lewis V; Chan KW; Horn B; Yu L; Talano JA; Nemecek E; Mills CR; Chaudhury S
Biol Blood Marrow Transplant; 2014 Feb; 20(2):229-35. PubMed ID: 24216185
[TBL] [Abstract][Full Text] [Related]
8. Combination Therapy with Inolimomab and Etanercept for Severe Steroid-Refractory Acute Graft-versus-Host Disease.
van Groningen LF; Liefferink AM; de Haan AF; Schaap NP; Donnelly JP; Blijlevens NM; van der Velden WJ
Biol Blood Marrow Transplant; 2016 Jan; 22(1):179-82. PubMed ID: 26386320
[TBL] [Abstract][Full Text] [Related]
9. Tocilizumab as first-line therapy for steroid-refractory acute graft-versus-host-disease: analysis of a single-center experience.
Yucebay F; Matthews C; Puto M; Li J; William B; Jaglowski SM; Penza SL; Vasu S; Benson DM; Andritsos LA; Devine SM; Efebera YA; Roddy JVF
Leuk Lymphoma; 2019 Sep; 60(9):2223-2229. PubMed ID: 30764681
[TBL] [Abstract][Full Text] [Related]
10. Low-dose alemtuzumab vs. standard policy for prevention of graft-versus-host disease in unrelated and related allogeneic stem cell transplantation-a matched pair analysis.
Busemann C; Neumann T; Schulze M; Klenner A; Thiele T; Greinacher A; Dölken G; Krüger WH
Ann Hematol; 2013 Jul; 92(7):945-52. PubMed ID: 23463451
[TBL] [Abstract][Full Text] [Related]
11. Pentostatin for treatment of steroid-refractory acute GVHD: a retrospective single-center analysis.
Schmitt T; Luft T; Hegenbart U; Tran TH; Ho AD; Dreger P
Bone Marrow Transplant; 2011 Apr; 46(4):580-5. PubMed ID: 20562925
[TBL] [Abstract][Full Text] [Related]
12. Infliximab for steroid refractory or dependent gastrointestinal acute graft-versus-host disease in children after allogeneic hematopoietic stem cell transplantation.
Yang J; Cheuk DK; Ha SY; Chiang AK; Lee TL; Ho MH; Chan GC
Pediatr Transplant; 2012 Nov; 16(7):771-8. PubMed ID: 22905718
[TBL] [Abstract][Full Text] [Related]
13. Successful treatment of severe acute intestinal graft-versus-host resistant to systemic and topical steroids with alemtuzumab.
Schnitzler M; Hasskarl J; Egger M; Bertz H; Finke J
Biol Blood Marrow Transplant; 2009 Aug; 15(8):910-8. PubMed ID: 19589480
[TBL] [Abstract][Full Text] [Related]
14. A novel GVHD-prophylaxis with low-dose alemtuzumab in allogeneic sibling or unrelated donor hematopoetic cell transplantation: the feasibility of deescalation.
Bertz H; Spyridonidis A; Wäsch R; Grüllich C; Egger M; Finke J
Biol Blood Marrow Transplant; 2009 Dec; 15(12):1563-70. PubMed ID: 19896080
[TBL] [Abstract][Full Text] [Related]
15. [Clinical study on recombinant humanized anti-CD25 monoclonal antibody used for treating steroid-resistant acute graft versus host disease following allo-hematopoietic stem cell transplantation].
Li XH; Gao CJ; DA WM; Cao YB; Xu LX; Wu YM; Liu B; Liu ZY; Yan B; Li SW; Yang XL; Wu XX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Dec; 21(6):1535-40. PubMed ID: 24370044
[TBL] [Abstract][Full Text] [Related]
16. Therapy of steroid-refractory acute GVHD with CD52 antibody alemtuzumab is effective.
Schub N; Günther A; Schrauder A; Claviez A; Ehlert C; Gramatzki M; Repp R
Bone Marrow Transplant; 2011 Jan; 46(1):143-7. PubMed ID: 20348971
[TBL] [Abstract][Full Text] [Related]
17. The successful use of alemtuzumab for treatment of steroid-refractory acute graft-versus-host disease in pediatric patients.
Khandelwal P; Lawrence J; Filipovich AH; Davies SM; Bleesing JJ; Jordan MB; Mehta P; Jodele S; Grimley MS; Kumar A; Myers K; Marsh RA
Pediatr Transplant; 2014 Feb; 18(1):94-102. PubMed ID: 24384050
[TBL] [Abstract][Full Text] [Related]
18. The effect of in vivo T cell depletion with alemtuzumab on reduced-intensity allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia.
Delgado J; Pillai S; Benjamin R; Caballero D; Martino R; Nathwani A; Lovell R; Thomson K; Perez-Simon JA; Sureda A; Kottaridis P; Vazquez L; Peggs K; Sierra J; Milligan D; Mackinnon S
Biol Blood Marrow Transplant; 2008 Nov; 14(11):1288-97. PubMed ID: 18940684
[TBL] [Abstract][Full Text] [Related]
19. Busulfan, fludarabine, and alemtuzumab as a reduced toxicity regimen for children with malignant and nonmalignant diseases improves engraftment and graft-versus-host disease without delaying immune reconstitution.
Law J; Cowan MJ; Dvorak CC; Musick L; Long-Boyle JR; Baxter-Lowe LA; Horn B
Biol Blood Marrow Transplant; 2012 Nov; 18(11):1656-63. PubMed ID: 22609040
[TBL] [Abstract][Full Text] [Related]
20. [Anti-CD25 monoclonal antibody with antithymocytic globulin for steroid-resistant severe acute graft-versus-host disease after unrelated donor hematopoietic stem cell transplantation].
Ye CX; Sun J; Liu QF; Qu H; Xu D; Zhang Y; Meng FY
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Dec; 28(12):2224-6. PubMed ID: 19114364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
